Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) an Israel-based pharmaceutical technology company, announced on Friday that it has added Dr Joseph V. Pergolizzi, Jr to its Scientific Advisory Board (SAB).

In the new role, Dr Pergolizzi is to concentrate on promoting pharmaceutical human product R&D and FDA filing, as outlined in his Advisory Board member services agreement.

Dr Pergolizzi has served in various C-level positions in private and public companies. He is a senior partner at Naples Anesthesia and Pain Associates and held the position of chief operating officer at NEMA Research Inc. He serves as a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a consultant to the National Pain Foundation board of directors. He is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He has worked as a part-time adjunct assistant professor in the Department of Medicine at the Johns Hopkins University School of Medicine.